http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019203694-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_069e4f0beeb200f48927489d2e704b64 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-00 |
| filingDate | 2019-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9c8b21399916e616a2496cb2f2e15b4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b17361bb79151745cc811f4129f6419a |
| publicationDate | 2019-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2019203694-A1 |
| titleOfInvention | Stable highly concentrated aqueous compositions of ranibizumab with prolonged action |
| abstract | The invention relates to the field of biotechnology, specifically to the problem of creating stable highly concentrated aqueous compositions of a medicinal preparation for intravitreal injections having a prolonged action. A stable aqueous pharmaceutical composition is proposed, comprising ranibizumab in a concentration of 100-300 mg/ml, which provides improved pharmacokinetic properties of a preparation upon intravitreal administration. The preparation is stable for 5 years at a temperature of +2-8ºС. The invention can be used in the pharmaceutical industry, specifically in the creation of a medicinal preparation for treating: the wet form of age-related macular degeneration in adults (ARMD); a reduction in visual acuity with diabetic macular oedema; a reduction in visual acuity as a consequence of macular oedema caused by retinal vein occlusion (of the central retinal vein or of branches thereof); and a reduction in visual acuity caused by choroidal neovascularization resulting from pathological myopia. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023031478-A1 |
| priorityDate | 2018-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 173.